OmniAb / Avista Public Acquisition Corp. II — Form 8-K Summary
Business context and reporting period
Avista Public Acquisition Corp. II (APAC), a Cayman Islands special purpose acquisition company, filed a Form 8-K dated June 21, 2022. The filing relates to the proposed business combination between APAC, Ligand Pharmaceuticals Incorporated, and OmniAb, Inc., Ligand’s antibody discovery business and wholly owned subsidiary.
Key disclosure
- APAC and Ligand previously entered into definitive agreements on March 23, 2022 for a transaction combining APAC with OmniAb.
- The filing furnishes an OmniAb analyst teach-in presentation dated June 21, 2022 as Exhibit 99.1.
- The presentation was used in connection with the proposed business combination and is incorporated by reference into Item 7.01 for disclosure purposes.
- The information, including the presentation, is furnished under Regulation FD and is not deemed “filed” under Section 18 of the Exchange Act, except where specifically incorporated by reference.
Financial metrics and material changes
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, valuation, operating forecasts, or other financial metrics. It is a disclosure of an analyst presentation rather than a periodic financial report. The filing text also does not describe material changes versus a prior comparable period.
Guidance, outlook, risks, and contingencies
The filing text does not provide the contents of the attached analyst presentation and therefore does not state specific guidance, transaction projections, risks, contingencies, or management commentary beyond identifying the proposed business combination. Investors should review Exhibit 99.1 and the definitive transaction documents for those details.
Important facts to verify
- Review the terms, conditions, required approvals, closing timeline, and termination provisions of the APAC–Ligand–OmniAb transaction.
- Review Exhibit 99.1 for OmniAb’s business description, market opportunity, operating data, projections, and risk disclosures.
- Confirm the treatment of Ligand’s OmniAb business, including ownership, capitalization, consideration, and post-closing governance.
- Verify any investor redemption, financing, or dilution implications associated with the SPAC transaction.
- Note that the filing identifies APAC—not OmniAb—as the registrant and furnishes the presentation rather than reporting standalone OmniAb financial results.